title: Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT.
abstract: OBJECTIVE
  To compare fat-suppressed, gadolinium-enhanced, breath-hold magnetic resonance (MR) imaging after administration of dilute oral barium solution with unenhanced MR imaging and computed tomography (CT) in the detection of peritoneal tumors.
  
  
  METHODS
  In 24 patients in whom peritoneal tumor was known or suspected, double-contrast MR imaging and CT were performed prospectively. MR imaging included T1-weighted, fast spin-echo T2-weighted, and immediate and delayed gadolinium-enhanced, breath-hold, fast multiplanar sequences with fat saturation. Helical and conventional dynamic CT were performed with intravenously and orally administered contrast media. MR images and CT scans were reviewed independently and prospectively by different pairs of radiologists for presence of peritoneal tumor in 17 anatomic sites. Imaging findings were compared with surgical and histopathologic results.
  
  
  RESULTS
  Of the 24 patients, 18 had peritoneal tumor confirmed at surgery. Detection of tumor sites was superior with double-contrast MR images (mean sensitivity, specificity, and accuracy, 84%, 87%, and 86%, respectively) compared with CT scans (mean sensitivity, specificity, and accuracy, 54%, 91%, and 74%, respectively). Double-contrast MR imaging enabled better detection of carcinomatosis and tumors less than 1 cm in diameter (75%-80%) than CT (22%-33%; P < .0001).
  
  
  CONCLUSIONS
  Double-contrast MR imaging demonstrated more peritoneal tumors than CT or unenhanced spin-echo MR imaging.
authors.affiliation: Department of Diagnostic Radiology, Sharp and Children's MRI Center, San Diego, CA 92123, USA.
authors.forename: R N
authors.initials: RN
authors.lastname: Low
authors.forename: R M
authors.initials: RM
authors.lastname: Barone
authors.forename: C
authors.initials: C
authors.lastname: Lacey
authors.forename: J S
authors.initials: JS
authors.lastname: Sigeti
authors.forename: G D
authors.initials: GD
authors.lastname: Alzate
authors.forename: C P
authors.initials: CP
authors.lastname: Sebrechts
mesh_terms: D000284:Administration, Oral; D001466:Barium Sulfate; D003287:Contrast Media; D004338:Drug Combinations; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D005934:Glucagon; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007275:Injections, Intravenous; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine; D008875:Middle Aged; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives; D010534:Peritoneal Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D011446:Prospective Studies; D011553:Pseudomyxoma Peritonei / Q000175:diagnosis; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D001466:Barium Sulfate; D008536:Meglumine; D004369:Pentetic Acid; D005934:Glucagon; D005682:Gadolinium; D019786:Gadolinium DTPA